Hillman Solutions Corp. (HLMN) closed the last trading session at $8, gaining 5.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.94 indicates a 36.8% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $2.54. While the lowest estimate of $8.00 indicates no increase from the current price level, the most optimistic analyst e ...

股价表现与目标价分析 - GDS Holdings最新收盘价为35 27美元 过去四周涨幅达14 4% 华尔街分析师给出的平均目标价为44 17美元 隐含25 2%上行空间 [1] - 12份目标价预测区间为28 30至64 54美元 标准差为9 75美元 最低目标价隐含19 8%跌幅 最高目标价隐含83%涨幅 标准差反映分析师预测分歧程度 [2] - 分析师共识目标价虽受投资者关注 但单纯依赖该指标做投资决策存在风险 因分析师目标价设定能力与客观性长期受质疑 [3] 盈利预测修正 - 分析师普遍上调GDS盈利预测 显示对公司盈利前景的乐观情绪增强 盈利预测修正趋势与短期股价走势存在强相关性 [4][11] - Zacks一致预期显示当前年度EPS预测过去一个月上调5 1% 仅见正面修正而无负面调整 [12] - GDS目前获Zacks Rank 1(强力买入)评级 位列4000多只股票前5% 该评级基于盈利预测相关四项因素 具有审计验证的可靠记录 [13] 目标价有效性研究 - 全球多所大学研究表明 分析师目标价误导投资者的频率高于指导作用 实证显示无论共识程度如何 目标价鲜少准确预测股价实际走向 [7] - 华尔街分析师虽掌握公司基本面数据 但常因商业利益(如维护客户关系)设定过度乐观目标价 [8] - 低标准差目标价集群反映分析师对股价方向与幅度高度共识 可作为研究基本面驱动力的起点 但不保证达到平均目标价 [9] 综合评估框架 - 投资者不应完全忽视目标价 但仅凭此决策可能导致投资回报不佳 需保持审慎态度 [10] - 尽管共识目标价可靠性存疑 但其暗示的股价方向仍具参考价值 结合盈利预测修正趋势可增强判断准确性 [14]

Dyne Therapeutics, Inc. (DYN) closed the last trading session at $9.91, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $38.21 indicates a 285.6% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $14.79. While the lowest estimate of $9.00 indicates a 9.2% decline from the current price level, the most optimistic anal ...

Zevra Therapeutics股票表现及分析师预测 - Zevra Therapeutics(ZVRA)股价在过去四周上涨16.8%至10.99美元 华尔街分析师给出的平均目标价23.86美元暗示仍有117.1%上行空间 [1] - 7位分析师目标价的标准差为3.39美元 最低目标价19美元(潜在涨幅72.9%) 最高目标价29美元(潜在涨幅163.9%) [2] - Zacks共识预期显示当前年度盈利预测过去30天增长337.1% 且无负面修正 [12] 分析师目标价的有效性分析 - 实证研究表明目标价常误导投资者 分析师对股价实际走向的判断准确率有限 [7] - 分析师可能因商业合作关系设定过度乐观目标价 但低标准差显示群体共识时参考价值提升 [8][9] - 目标价应保持审慎态度 不宜作为唯一投资决策依据 [10] 盈利预测修正的指示意义 - 分析师集体上调EPS预期的行为与短期股价走势存在强相关性 [11] - 公司当前获Zacks评级第二级(买入) 位列4000多只股票前20% 显示近期的上涨潜力 [13] - 盈利预测修正趋势比目标价更能可靠指示股价变动方向 [14] 投资参考框架 - 目标价离散度分析显示 低标准差(3.39美元)意味着分析师对上涨方向和幅度存在高度共识 [2][9] - 结合Zacks评级提升与盈利预测大幅上调 基本面支撑股价继续走强 [12][13] - 建议将目标价作为研究起点 而非绝对依据 需深入挖掘基本面驱动因素 [9][10]

Shares of uniQure (QURE) have gained 1.3% over the past four weeks to close the last trading session at $14.46, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.09 indicates a potential upside of 142.7%.The mean estimate comprises 11 short-term price targets with a standard deviation of $17.1. While the lowest estimate of $13.00 indicates a 10.1% decline from the current pric ...

Wall Street analysts forecast that PSEG (PEG) will report quarterly earnings of $0.71 per share in its upcoming release, pointing to a year-over-year increase of 12.7%. It is anticipated that revenues will amount to $2.34 billion, exhibiting a decrease of 3.2% compared to the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Pri ...

West Pharmaceutical Services (WST) closed the last trading session at $252.94, gaining 13.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $316.82 indicates a 25.3% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $34.23. While the lowest estimate of $260.00 indicates a 2.8% increase from the current price level, the most optim ...

Shares of Genius Sports Limited (GENI) have gained 0.7% over the past four weeks to close the last trading session at $10.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.82 indicates a potential upside of 26.1%.The average comprises 17 short-term price targets ranging from a low of $11.00 to a high of $15.00, with a standard deviation of $1.13. While the lowest estimate ...

Nomad Foods (NOMD) closed the last trading session at $17.49, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24 indicates a 37.2% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $2.37. While the lowest estimate of $20.00 indicates a 14.4% increase from the current price level, the most optimistic analyst expects ...

HNI (HNI) closed the last trading session at $51.83, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $68.75 indicates a 32.7% upside potential.The average comprises four short-term price targets ranging from a low of $60.00 to a high of $80.00, with a standard deviation of $8.54. While the lowest estimate indicates an increase of 15.8% from the current price level, the ...